Anavex 2-73 Demonstrates Potential in Reducing Parkinson’s Symptoms
Anavex Life Sciences has reported promising results from an extension study of its investigational
therapy, Anavex 2-73 (blarcamesine), for Parkinson’s disease dementia. The
findings, which come from an extension of the Phase 2 ANAVEX 2-73-PDD-001
trial, highlight the drug’s potential in reducing both motor and cognitive
symptoms over a prolonged period.
According to the study, 20 participants who completed a year-long treatment with Anavex 2-73
showed a significant reduction in the severity of their symptoms. Remarkably,
this improvement stands in contrast to the symptom worsening observed during a
drug holiday between the initial Phase 2 trial and the extension study. This
suggests that continuous administration of the drug may be crucial for
maintaining its therapeutic benefits.
Anavex 2-73 is an orally administered small molecule that activates SIGMAR1, a receptor involved
in neuroprotection and cellular homeostasis. By targeting this receptor, Anavex 2-73 aims to preserve healthy brain cells, thereby offering a new
avenue for treating neurodegenerative diseases.
The study’s results were evaluated using the Movement Disorder Society-Unified Parkinson’s Disease
Rating Scale (MDS-UPDRS), which assesses motor and non-motor symptoms.
Participants in the extension study experienced improvements in MDS-UPDRS
scores, indicating better overall health and slower cognitive decline.
Christopher Missling, PhD, President and CEO of Anavex, expressed optimism about the data. “These findings suggest Anavex
2-73’s potential to slow and possibly reverse the debilitating symptoms of
Parkinson’s disease,” he stated.
Anavex Life Sciences is preparing to launch a pivotal Phase 3 trial to further evaluate the
efficacy of Anavex 2-73. This upcoming trial aims to substantiate the drug’s
benefits, focusing on a larger patient pool over a six-month period.
As the medical community eagerly awaits further data, Anavex continues to position Anavex 2-73
as a promising candidate in the fight against Parkinson’s disease and related
neurodegenerative conditions. Visit this page on LinkedIn, for related information.
Follow their page on twitter.com